Le Lézard
Classified in: Health
Subjects: SVY, AVO

Parkinson Canada Roundtable Report explores advocacy needs of Ontarians living with Parkinson's


TORONTO, May 16, 2022 /CNW/ - The Parkinson Canada Ontario Advocacy Roundtable Report, the first in a provincial series of reports following the National Advocacy Roundtable Report, launches this week.

More than 150 community members, including people living with Parkinson's, their care partners, community organizations, healthcare specialists and government officials from across Canada participated in a nine-part series of roundtable discussions, which led to the creation of the report.

The reports explore the healthcare realities and needs of the 100,000+ Canadians living with Parkinson's and are the first step in building the foundation of future advocacy efforts for Parkinson Canada.

Findings from the Ontario report include the following key facts regarding Ontarians living with Parkinson's:

Findings from the Ontario report include the following key priorities for improving the quality of life for people living with Parkinson's in the province:

These priorities will provide a roadmap to the organization in developing our future advocacy work in supporting Ontarians affected by Parkinson's.

"There's a sense of urgency with Parkinson's and the growing number of people being diagnosed, and with that, a need for change to systemic barriers in healthcare to allow for things like earlier diagnosis and treatment, which will ultimately lead to a better quality of life for people living with Parkinson's," says Karen Lee, PhD, president and CEO, Parkinson Canada. "The Roundtable Reports provide a roadmap for the development of our future advocacy work to support those affected by Parkinson's."

Parkinson's is a chronic, progressive neurodegenerative disease caused by a loss of dopamine-producing neurons in areas of the brain associated with movement. It is one of the fastest-growing neurological diseases in the world and Canada has one of the highest prevalence rates compared to other countries. More than 100,000 people in Canada live with Parkinson's and that number will grow by about 30 people a day.

For more on the roundtables and to download the reports, visit our website: Parkinson.ca/advocacy. The roundtables and National Roundtable Report were supported in part with funding from AbbVie.

About Parkinson's and Parkinson Canada

More than 100,000 Canadians live with Parkinson's, a number expected to increase substantially in the coming years, with 30 Canadians diagnosed each day.

Parkinson's is a chronic, progressive neurodegenerative disease caused by a loss of dopamine-producing neurons in areas of the brain associated with movement. Symptoms include a resting tremor, slowness of movement, muscle rigidity, and balance problems. Non-motor symptoms can include anxiety, depression, and sleep problems. The average age of diagnosis is 60, but some people are diagnosed prior to that and referred to as having early onset Parkinson's.

People with Parkinson's are at the centre of everything we do. Our mission is to transform the lives of people living with Parkinson's. Parkinson Canada funds critical research, provides information and support, increases awareness and advocates for improved healthcare outcomes for people with Parkinson's across Canada. The Parkinson Canada Research Program, which includes the Canadian Open Parkinson Network (C-OPN), funds innovative research for better treatments and a cure. A national registered charity, Parkinson Canada fulfils its mission through the generosity of donors and is an accredited organization under the Imagine Canada Standards Program since 2013.

Please visit parkinson.ca or call 1-800-565-3000 for more information, to get involved or to support Canadians affected by Parkinson's by making a donation.

Join the conversation, find Parkinson Canada on Facebook, Twitter and Instagram.

SOURCE Parkinson Canada


These press releases may also interest you

at 17:31
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness. Moreover,...

at 17:00
Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private...

at 16:46
Darling Ingredients Inc. announced today that it will host a conference call on Thursday, April 25, 2024, at 9 a.m. Eastern Time (8 a.m. Central Time) to discuss first quarter 2024 financial results, which will be released earlier that day, and...

at 16:45
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic...

at 16:45
Geron Corporation , a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection...

at 16:35
DermTech, Inc. (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring...



News published on and distributed by: